Psychiatry
M-A: Psychosocial and psychological interventions for relapse prevention in schizophrenia.
17 Oct, 2021 | 21:12h | UTC
Commentary on Twitter
An excellent SR/Network MA on #Psychosocial interventions for relapse prevention in #schizophrenia
Family interventions, family psychoeducation, & CBT are effective & must be prioritised in the care systems for patients with schizophrenia @TheLancetPsych https://t.co/d6xRw14fbT— Rajesh Mohan🌈 (@raj_psyc) October 16, 2021
RCT: Oxytocin does not improve social functioning in children with autism spectrum disorder.
14 Oct, 2021 | 09:52h | UTCOriginal study: Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder – New England Journal of Medicine
New Global Burden of Disease analyses show depression and anxiety among the top causes of health burden worldwide, and a significant increase due to the COVID-19 pandemic.
10 Oct, 2021 | 21:57h | UTCCommentaries:
Depression and anxiety disorders during the COVID-19 pandemic: knowns and unknowns – The Lancet
Covid crisis dramatically worsened global mental health, study finds – The Guardian
Commentary on Twitter (thread – click for more)
✨🆕–The #COVID19 pandemic led to a stark rise in depressive and anxiety disorders globally in 2020 w/women & younger people most affected, according to a new study by our researchers & collaborators published today in @TheLancet. #GBDstudy #MentalHealth
»https://t.co/qXEDzn3idV pic.twitter.com/4xsofBXyvS
— Institute for Health Metrics and Evaluation (IHME) (@IHME_UW) October 8, 2021
World Mental Health Day: prioritize social justice, not only access to care.
10 Oct, 2021 | 21:37h | UTCWorld Mental Health Day: prioritise social justice, not only access to care – The Lancet (free registration required)
Commentary on Twitter
"…under the wrong set of social circumstances, everyone is vulnerable to mental health problems."#WorldMentalHealthDay: prioritise social justice, not only access to care—a Comment by Soumitra Pathare @netshrink and colleagues. https://t.co/AwdSXo8y5H pic.twitter.com/Az6AB9vLmm
— The Lancet (@TheLancet) October 10, 2021
Editorial: Brain health and its social determinants.
10 Oct, 2021 | 21:35h | UTCBrain health and its social determinants – The Lancet
Commentary on Twitter
Globally, action to tackle the social determinants of mental ill health—including poverty, racism, and discrimination—remains a low priority in too many countries.
On #WorldMentalHealthDay, read our Editorial: https://t.co/VRJkZ8kVn5#MentalHealth #WMHD2021 pic.twitter.com/hxvrCoMbt0
— The Lancet (@TheLancet) October 10, 2021
M-A: Accuracy of the Patient Health Questionnaire-9 for screening to detect major depression.
10 Oct, 2021 | 21:34h | UTCSee calculator: PHQ-9 (Patient Health Questionnaire-9)
Commentary on Twitter
This new study investigates the accuracy of the Patient Health Questionnaire-9 (PHQ-9), the most commonly used depression screening tool in general practice, for detecting major depression https://t.co/9WoI3MofWH
— The BMJ (@bmj_latest) October 10, 2021
Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies.
10 Oct, 2021 | 21:31h | UTC
The German Guidelines for the treatment of anxiety disorders.
8 Oct, 2021 | 10:16h | UTC
Saying ‘person with schizophrenia,’ not ‘schizophrenic,’ can affect clinician beliefs, study finds.
1 Oct, 2021 | 10:05h | UTCOriginal article: It’s Time for Counselors to Modify Our Language: It Matters When We Call Our Clients Schizophrenics Versus People With Schizophrenia – Journal of Counseling & Development ($)
RCT: Maintenance vs. discontinuation of antidepressants in patients who felt well enough to discontinue antidepressant therapy.
30 Sep, 2021 | 10:22h | UTCMaintenance or Discontinuation of Antidepressants in Primary Care – New England Journal of Medicine
Commentaries:
Many can stop anti-depressants without relapse – BBC
Study highlights difficulty of stopping antidepressants – Associated Press
Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review.
30 Sep, 2021 | 10:07h | UTC
Commentary on Twitter
Review: Methylphenidate is effective both against the core ADHD symptoms (SMD=0.49; 0.35–0.64), and the emotion regulation deficits (SMD=0.34; 0.23–0.45) in adults with ADHD. Long-term AEs: decreased appetite, dry mouth, heart palpitations, agitation https://t.co/V73jPK58pL
— PfOL (@psychopharmacol) September 25, 2021
M-A: Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults.
29 Sep, 2021 | 10:04h | UTCInvited Commentary: Treatment-Resistant Depression—Resistant to Placebos as Well? – JAMA Network Open
Commentaries on Twitter
This systematic review and meta-analysis found that in studies of patients with treatment-resistant depression, the placebo effect was large and consistent despite the modality use. https://t.co/U6efJo7rJ8
— JAMA Network Open (@JAMANetworkOpen) September 24, 2021
Important systematic review study: The placebo effect in clinical trials of depression, even if treatment-resistant, is huge!
Magnitude of the Placebo Response Across Treatment-Resistant Depression in Adults https://t.co/ey2hIpE61r via @JAMANetworkOpen part of @JAMANetwork
— Yasser Ad-Dab'bagh (@yasseraddabbagh) September 25, 2021
Question
Why does research on 'treatment resistance' have such high placebo response?3 Answers
1)Research patients arent nearly as sick as patients in clinical practice
2)Research patients get much more attention than clinical patients
3)Research raises very high expectations https://t.co/f8CyTpKofV— Allen Frances (@AllenFrancesMD) September 26, 2021
(thread – click for more)
The paradox of "treatment resistance" in psychiatry that doesn't seem to generate much discussion: if the depression is so treatment resistant that we are considering things like invasive brain stimulation, how come it responds to "placebo" so robustly?/1https://t.co/oQOBPXtVXO
— Awais Aftab (@awaisaftab) September 26, 2021
RCT: Methylphenidate may improve apathy in patients with Alzheimer Disease.
28 Sep, 2021 | 09:06h | UTCEffect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial – JAMA Neurology (free for a limited period)
Editorial: Methylphenidate for Apathy in Alzheimer Disease—Why Should We Care? (free for a limited period)
Commentary on Twitter
Small to medium effects of methylphenidate for apathy in AD. Good to see a positive symptomatic treatment trial but I wonder just how important the improvements are to patients and their families. https://t.co/nGSxlAntAd
— Robert Howard (@ProfRobHoward) September 27, 2021
M-A of randomized trials: Efficacy of exercise combined with standard treatment for depression compared to standard treatment alone.
28 Sep, 2021 | 08:55h | UTC
Commentary on Twitter
Meta-analysis: Exercise combined with standard treatments for depression is more effective than standard treatments alone. https://t.co/TlePIyvzo3 pic.twitter.com/h6eRoKFLUt
— Steve Stewart-Williams (@SteveStuWill) September 18, 2021
Cohort Study: Insulin resistance linked to increased risk of major depressive disorder.
24 Sep, 2021 | 08:59h | UTCCommentaries:
Insulin Resistance Linked to Major Depressive Disorder, Dutch Study Finds – Psychiatric News Alert
Insulin resistance doubles risk of major depressive disorder – Stanford Medicine
RCT: Preemptive intervention may improve developmental outcomes in infants showing early signs of autism.
21 Sep, 2021 | 09:01h | UTCEffect of Preemptive Intervention on Developmental Outcomes Among Infants Showing Early Signs of Autism: A Randomized Clinical Trial of Outcomes to Diagnosis – JAMA Pediatrics (free for a limited period)
Commentaries:
Autism therapy aimed at infants may reduce likelihood of later diagnosis – The Guardian
Commentary on Twitter
An Australian randomized clinical trial found that ‘pre-emptive’ therapy during infancy reduced #autism diagnostic behaviors and improved language ability across early childhood https://t.co/Sybbu4hRWL
— JAMA Pediatrics (@JAMAPediatrics) September 20, 2021
5000 alcohol-related cancer deaths could be prevented every year by doubling alcohol taxes in the European Region, says WHO/Europe.
21 Sep, 2021 | 08:52h | UTCRelated:
Fiscal policies for diet and the prevention of noncommunicable diseases – World Health Organization
The Lancet taskforce on NCDs and economics
To improve global health, tax the things that are killing us – Financial Times
Reducing cardiovascular disease burden through targeted dietary policies
Fiscal policies for the prevention of diseases
Editorial: Brain health and its social determinants.
19 Sep, 2021 | 23:28h | UTCBrain health and its social determinants – The Lancet
Commentary on Twitter
Strong statement from @TheLancet on social determinants of mental health. The American Psychiatric Association has embraced it, as has @rcpsych https://t.co/JfRcj7KXvq
— Sir Michael Marmot (@MichaelMarmot) September 17, 2021
Lamotrigine in the maintenance treatment of bipolar disorder.
19 Sep, 2021 | 23:25h | UTCLamotrigine in the maintenance treatment of bipolar disorder – Cochrane Library
Summary: Lamotrigine as a treatment for prevention of recurrence of bipolar disorder – Cochrane Library
What an enormous global study can tell us about feeling better during the pandemic.
10 Sep, 2021 | 05:27h | UTCWhat an enormous global study can tell us about feeling better during the pandemic – Vox
Original study: A multi-country test of brief reappraisal interventions on emotions during the COVID-19 pandemic – Nature Human Behavior
New Canadian study confirms the excess mortality associated with eating disorders.
10 Sep, 2021 | 05:03h | UTCNew Canadian study confirms the excess mortality associated with eating disorders – The Mental Elf
Original study: Excess mortality associated with eating disorders: population-based cohort study – The British Journal of Psychiatry
Commentary on Twitter
Today, @annapaspala1 summarises a new study by @KurdyakP et al, published today in @TheBJPsych, which suggests that in Ontario (Canada), mortality rates in people with eating disorders were 5-7 times higher than the general population.https://t.co/P2QmU3Qxg8 pic.twitter.com/7VrpsevF5P
— The Mental Elf (@Mental_Elf) September 1, 2021
Editorial | Anticholinergic drugs and dementia: time for transparency in the face of uncertainty.
9 Sep, 2021 | 08:57h | UTCSystematic review: Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome – Cochrane Library
Commentary on Twitter
Anticholinergic drugs may double the risk of developing dementia. What should we be doing right now?
Editorial with @JenMStevenson for @CochraneLibrary published todayhttps://t.co/808wSGPUtm— Henry Woodford (@woodford_henry) September 8, 2021
Recent cannabis use linked to increased risk of myocardial infarction in young adults: a cross-sectional study.
7 Sep, 2021 | 21:38h | UTCNews release: Recent cannabis use linked to heart attack risk in younger adults – Canadian Medical Association Journal
Commentary: Young adult cannabis consumers nearly twice as likely to suffer from a heart attack, research shows – CNN
M-A: Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia.
6 Sep, 2021 | 10:40h | UTCLong-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link to abstract – $ for full-text)
Commentary on Twitter
"Taken together, the results suggest increased use of long-acting injectable antipsychotics in clinical practice should be considered."
New Researchhttps://t.co/l2Ow9BzCUu
— The Lancet Psychiatry (@TheLancetPsych) April 14, 2021
M-A: Effect of monthly injections of naltrexone on alcohol consumption.
6 Sep, 2021 | 10:39h | UTCEffect of extended-release naltrexone on alcohol consumption: a systematic review and meta-analysis – Addiction (link to abstract – $ for full-text)